We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell (OMCL) Down 5.6% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Omnicell (OMCL - Free Report) . Shares have lost about 5.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Omnicell due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Omnicell Q4 Earnings Miss Estimates, Revenues Beat
Omnicell, Inc. reported fourth-quarter 2021 adjusted earnings per share of 92 cents, up 1.1% year over year. However, the metric missed the Zacks Consensus Estimate by 3.2%.
The adjustments include one-time expenses like share-based compensation, amortization of acquired intangibles, acquisition-related expenses and others.
On a GAAP basis, earnings per share were 28 cents for the quarter under review, reflecting a 24.3% fall from EPS of 37 cents reported in the year-ago quarter.
For the full year, adjusted earnings were $3.81 per share, up 50% from the year-ago period. This figure was in line with the Zacks Consensus Estimate.
Revenues in Detail
Fourth-quarter revenues of $311.03 million rose 24.8% year over year on a reported basis. The figure beat the Zacks Consensus Estimate by 0.3%.
Total revenues for 2021 were $1.13 billion, up 26.9% from the year-ago period. This figure met the Zacks Consensus Estimate.
Segmental Details
On a segmental basis, Product revenues rose 27.2% year over year to $223.5 million in the reported quarter.
Service and other revenues climbed 19% year over year to $87.5 million.
Operational Update
In the quarter under review, company-adjusted gross profit rose 20.7% to $149.3 million. Company-adjusted gross margin contracted 162 basis points (bps) to 48%.
Operating expenses were $137.7 million in the fourth quarter, up 33.1% year over year. Operating profit totaled $11.6 million, reflecting a 42.7% fall from the prior-year quarter. Operating margin in the fourth quarter contracted 439 bps to 3.7%.
Financial Update
Omnicell exited full-year 2021 with cash and cash equivalents of $349.1 million compared with $485.9 million at the end of 2020.
Cumulative cash flow from operating activities at the end of 2021 was $231.8 million compared with $185.9 million a year ago.
Guidance for Q1 & 2022
Omnicell has provided its guidance for the first quarter and full-year 2022, which considers the expected contributions of ReCept, MarkeTouch Media, the previously-acquired FDS Amplicare, the integration costs of such acquisitions and the anticipated effects of the current inflationary environment.
For the first quarter of 2022, Omnicell expects revenues between $312 million and $318 million. The Zacks Consensus Estimate for the metric is pegged at $294.78 million. Product revenues are forecast between $216 million and $219 million, while service revenues are projected within $96 million and $99 million for the quarter.
First-quarter adjusted EPS is envisioned in the band of 65-72 cents. The Zacks Consensus Estimate for the same is pegged at 69 cents.
For the full year, the company anticipates product bookings in the range of $1.370 billion to $1.430 billion.
Revenues are estimated between $1.385 billion and $1.410 billion. The Zacks Consensus Estimate for the same stands at $1.28 billion.
For 2022, the currently-projected ranges for product and service revenues are $950-$965 million and $435-$445 million, respectively.
Full-year adjusted EPS is expected between $3.75 and $3.95. The Zacks Consensus Estimate for the metric stands at $4.17.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review.
VGM Scores
At this time, Omnicell has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Omnicell has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Omnicell (OMCL) Down 5.6% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Omnicell (OMCL - Free Report) . Shares have lost about 5.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Omnicell due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Omnicell Q4 Earnings Miss Estimates, Revenues Beat
Omnicell, Inc. reported fourth-quarter 2021 adjusted earnings per share of 92 cents, up 1.1% year over year. However, the metric missed the Zacks Consensus Estimate by 3.2%.
The adjustments include one-time expenses like share-based compensation, amortization of acquired intangibles, acquisition-related expenses and others.
On a GAAP basis, earnings per share were 28 cents for the quarter under review, reflecting a 24.3% fall from EPS of 37 cents reported in the year-ago quarter.
For the full year, adjusted earnings were $3.81 per share, up 50% from the year-ago period. This figure was in line with the Zacks Consensus Estimate.
Revenues in Detail
Fourth-quarter revenues of $311.03 million rose 24.8% year over year on a reported basis. The figure beat the Zacks Consensus Estimate by 0.3%.
Total revenues for 2021 were $1.13 billion, up 26.9% from the year-ago period. This figure met the Zacks Consensus Estimate.
Segmental Details
On a segmental basis, Product revenues rose 27.2% year over year to $223.5 million in the reported quarter.
Service and other revenues climbed 19% year over year to $87.5 million.
Operational Update
In the quarter under review, company-adjusted gross profit rose 20.7% to $149.3 million. Company-adjusted gross margin contracted 162 basis points (bps) to 48%.
Operating expenses were $137.7 million in the fourth quarter, up 33.1% year over year. Operating profit totaled $11.6 million, reflecting a 42.7% fall from the prior-year quarter. Operating margin in the fourth quarter contracted 439 bps to 3.7%.
Financial Update
Omnicell exited full-year 2021 with cash and cash equivalents of $349.1 million compared with $485.9 million at the end of 2020.
Cumulative cash flow from operating activities at the end of 2021 was $231.8 million compared with $185.9 million a year ago.
Guidance for Q1 & 2022
Omnicell has provided its guidance for the first quarter and full-year 2022, which considers the expected contributions of ReCept, MarkeTouch Media, the previously-acquired FDS Amplicare, the integration costs of such acquisitions and the anticipated effects of the current inflationary environment.
For the first quarter of 2022, Omnicell expects revenues between $312 million and $318 million. The Zacks Consensus Estimate for the metric is pegged at $294.78 million. Product revenues are forecast between $216 million and $219 million, while service revenues are projected within $96 million and $99 million for the quarter.
First-quarter adjusted EPS is envisioned in the band of 65-72 cents. The Zacks Consensus Estimate for the same is pegged at 69 cents.
For the full year, the company anticipates product bookings in the range of $1.370 billion to $1.430 billion.
Revenues are estimated between $1.385 billion and $1.410 billion. The Zacks Consensus Estimate for the same stands at $1.28 billion.
For 2022, the currently-projected ranges for product and service revenues are $950-$965 million and $435-$445 million, respectively.
Full-year adjusted EPS is expected between $3.75 and $3.95. The Zacks Consensus Estimate for the metric stands at $4.17.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review.
VGM Scores
At this time, Omnicell has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Omnicell has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.